Assessment Of Bcl-2 And CD14 In

SummaryB-CLL is a unique lymphoproliferative disorder that scarcely occurs under the age of 40. B-CLL represents a neoplastic disorder caused primarily by defective programmed cell death(PCD) and accompanied by a myriad of cellular and humoral immune defects.In Egypt the lymphoid malignancies constitute about 19.6% of total malignancies.The aim of this study is to asses Bcl-2 and CD14 expression in patients with chronic lymphocytic leukemia through their estimation by flow cytometry.This study was performed on (20) patients presented with CLL and 10 apparently healthy individuals served as control group. All patients and control groups of this study were subjected to the following:1-Full history taking and full clinical examination.2-Routine laboratory investigations.A-Complete blood count using automatic cell counter (Sysmex sf-3000).B-Peripheral blood examination by leishman stain.C-Serum lactate dehydrogenase (LDH) determination.D-Direct antiglobin (Coombs’) test.3-Immunophenotyping by FAC scan flowcytometry (Bickton Dicknson) using chronic lymphocytic leukaemia panel kit.4-Specific laboratory investigations:A) Flowcytometric assessment for Bcl-2.B) Flowcytometric assessment for CD14.In this study:-The aberrant expression of Bcl-2 protein in CLL was noted in all CLL patients (100%).-There was a significant difference in Bcl-2 expression between control and CLL groups.-There was a significant relationship between Bcl-2 expression with high white blood cells count, lymphocytic count and LDH level.-Bcl-2 was not associated with patient age, sex, hemoglobin concentration , platelets count and Rai stage.-The aberrant expression of myelo-monocytic antigen “CD14” above the cut-off value 5x109/l on CLL cells has been reported in 70% of cases.-There was a significant difference in CD14 expression between control and CLL groups.-In CLL group no statistically significant correlation was found between modified Rai stages on one hand and the absolute CD14+ cells on the other hand, in spite of the high expression of CD14+ cells in intermediate risk group 5/9 (55%) and 9/11 (82%) in high risk group were observed.-Investigating the relationship between CD14 and Bcl-2 expression in CLL patients, there was no any significant correlation found between them.Conclusion:There was significant increase in Bcl-2 protein and CD14 in CLL patients. Bcl-2 was highly increasesd in all patients and CD14 more observed in high risk groups than the intermediate risk group.